Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 15Thoracic 10Genitourinary 5Head & Neck 3Gynecologic 2Tumor-Agnostic 1Other solid neoplasm 1Other hematologic neoplasm 1

Conditions

Neoplasms 1Hematologic Neoplasms 1

Interventions

venetoclax 75Cyclophosphamide 68Cytarabine 59fludarabine 49Azacitidine 44Specimen Handling 36fludarabine phosphate 35Rituximab 34Biopsy 30Methotrexate 28ibrutinib 27Daunorubicin 25Dexamethasone 24Vincristine 23obinutuzumab 21Etoposide 21Decitabine 21acalabrutinib 19Tacrolimus 19Dasatinib 19blinatumomab 18Melphalan 18Prednisone 16Mycophenolic Acid 16Granulocyte Colony-Stimulating Factor 16Busulfan 16Whole-Body Irradiation 15Doxorubicin 15Injections 14pegaspargase 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × tremelimumab × Other hematologic neoplasm × Clear all
NCT03837899 2026-04-21

Durvalumab and Tremelimumab for Pediatric Malignancies

AstraZeneca

Phase 1/2 Active not recruiting
50 enrolled 59 charts
Other hematologic neoplasm

Neoplasms, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡